References
- Falkson G., Holcroft C., Gelman R. S., Tormey D. C., Wolter J. M., Cummings F. J. Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1995; 1453–1458
- Sledge G. W., Jr. Should we dream the impossible dream? The meaning of long-term survival in metastatic breast cancer. J Clin Oncol 1996; 14: 2191–2193
- Cardoso F., Di LA, Lohrisch C., Bernard C., Ferreira F., Piccart M. J. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?. Ann Oncol 2002; 13: 197–207
- Porkka K., Blomqvist C., Rissanen P., Elomaa I., Pyrhonen S. Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer. J Clin Oncol 1994; 12: 1639–1647
- Pierga J. Y., Robain M., Jouve M., Asselain B., Dieras V., Beuzeboc P., et al. Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients. Ann Oncol 2001; 12: 231–237
- Gennari A., Conte P., Rosso R., Orlandini C., Bruzzi P. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104: 1742–1750
- O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005; 10: 20–29
- Campora E., Gardin G., Gasco M., Rosso R., Santi L. Metastatic breast cancer patients failing first-line, anthracycline-containing chemotherapy: is further therapy of benefit?. Anticancer Res 1999; 19: 3429–3432
- Verma S., Clemons M. First-line treatment options for patients with HER-2 negative metastatic breast cancer: the impact of modern adjuvant chemotherapy. Oncologist 2007; 12: 785–797
- Fossati R., Confalonieri C., Torri V., Ghislandi E., Penna A., Pistotti V., et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998; 16: 3439–3460
- Kakolyris S., Kalbakis K., Potamianou A., Malamos N., Vamvakas L., Christophillakis C., et al. Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: a multicenter phase II study. Oncol 2006; 70: 273–239
- Ardavanis A., Kountourakis P., Maliou S., Vassilakopoulou M., Basioukas S., Kyriakou F., et al. Gemcitabine and oral vinorelbine as salvage treatment in patients with advanced anthracycline and taxane-pretreated breast cancer. Anticancer Res 2007; 27: 2989–2992
- Keller A. M., Mennel R. G., Georgoulias V. A., Nabholtz J. M., Erazo A., Lluch A., et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004; 22: 3893–3901